Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data [J]. Drug Metab Rev, 2002, 34: 83-448.
[2]
Guengerich FP. Human cytochrome P450 enzymes [A]. Ortiz de Montellano PR. Cytochrome P450,New York: Plenum, 1995:473-535.
[3]
Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver [J]. Pharmacogenetics, 2001, 11: 399-415.
Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis [J]. Hepatology, 2002, 35(4): 883-839.
[9]
Wen X, Wang J S, Neuvonen P J, et al. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 is of orms in human liver microsomes [J]. Eur J Clin Pharmacol, 2002, 57(11): 799-804.
[10]
Vuilleumie N, Rossier M F, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis [J]. Eur J Clin Pharmacol, 2006, 62(6): 423-429.
[11]
Miksys S, Lerman C, Shields PG, et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain [J]. Neuropharmacology, 2003, 45(1): 122-132.
